Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1061-1067

  Coon, John S ^a   Marcus, Elizabeth ^b   Gupta Burt, Shalina ^a   Seelig, Steven ^c   Jacobson, Kris ^c   Chen, Shande ^a   Renta, Vivian ^b   Fronda, Geraldo ^b   Preisler, Harvey D ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b Jr Hospital of Cook County   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MINIMAL RESIDUAL DISEASE; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0036554731     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McMasters, K. M., and Hunt, K. K. Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life. J. Clin. Oncol., 17: 441-444, 1999.
2. Colleoni, M., Minchella, I., Mazzarol, G., Nole, F., Peruzzotti, G., Rocca, A., Viale, G., Orlando, L., Ferretti, G., Curigliano, G., Veronesi, P., Intra, M., and Goldhirsch, A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann. Oncol., 11: 1057-1059, 2000.
3. Chang, J., Omerod, M., Powles, T. J., Allred, D. C., Ashley, S. E., and Dowsett, M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (Phila.), 89: 2145-2152, 2000.
4. Thor, A. S., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, I. C., Norton, L., and Liu, E. T. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1346-1360, 1998.
5. Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, M. E., and Wolmark, N. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1361-1370, 1998.
6. Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J.-Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R., and Flom, K. J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol., 15: 2894-2904, 1997.
7. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
8. Pegram, M. D., Ginn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15: 537-547, 1997.
9. Jarvinen, T. A. H., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., and Isola, J. Amplification and deletion of topoisomerase IIα associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol., 156: 839-847, 2000.
10. Robertson, K. W., Reeves, J. R., Smith, G., Keith, W. N., Ozanne, B. W., Cooke, T. G., and Stanton, P. D. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res., 56: 3823-3830, 1996.
11. Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., and Slamon, D. J. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol., 18: 3651-3664, 2000.
12. Thor, A. D., Liu, S., Edgerton, S., Moore, D., Kasowitz, K. M., Benz, C. C., Stern, D. F., and DiGiovanna, M. P. Activation (tyrosine phosphorylation) of erbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol., 18: 3230-3239, 2000.
13. Venkatesan, T. K., Kuropkat, C., Caldarelli, D. D., Panje, W. R., Hutchinson, J. C., Chen, S., and Coon, J. S. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope, 109: 1329-1333, 1999.
14. Hopman, A. H. N., Claessen, J. S., and Speel, E. J. M. Multi-color brightfield in situ hybridization on tissue section. Histochem. Cell Biol., 108: 291-298, 1997.
15. Vincent-Salomon, A., Carton, M., Frenaux, P., Palangie, T., Beuzeboc, P., Mouret, E., de Cremoux, P., Coue, O., Zafrani, B., Nicolas, A., Clough, K., Fourquet, A., Pouillart, P., and Sastre-Garau, X. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracyline-based chemotherapy. Eur. J. Cancer, 36: 586-591, 2000.
16. Nitiss, J. L., and Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer, 12A: 958-966, 1996.
17. Holden, J. A. Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs. Ann. Clin. Lab. Science, 27: 402-412, 1997.
18. Dingemans, A. C., Witlox, M. A., Stallaert, R.A.L.M., van der Valk, P., Postmus, P. E., and Giaccone, G. Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res., 5: 2048-2058, 1999.
19. Klumper, E., Giaccone, G., Pieters, R., Broekema, G., van Ark-Otte, J., van Wering, E. R., Kaspers, G. J. L., and Veerman, A. J. P. Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia (Baltimore), 9: 1653-1660, 1995.
20. Oloumi, A., Macphail, S. H., Johnston, P. J., Banath, J. P., and Olive, P. L. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res., 60: 5747-5753, 2000.
21. Baselga, J., Seidman, A. D., Rosen, P. P., and Norton, L. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology, 11 (Suppl. 2): 43-48, 1997.